A coronavirus assembly inhibitor that targets the viral membrane protein

  • Nature. 2025 Apr;640(8058):514-523. doi: 10.1038/s41586-025-08773-x.
Manon Laporte  #  1 ,  Dirk Jochmans  #  1 ,  Dorothée Bardiot  2 ,  Lowiese Desmarets  3 ,  Oliver J Debski-Antoniak  4 ,  Giulia Mizzon  5  6 ,  Rana Abdelnabi  1  7 ,  Pieter Leyssen  1 ,  Winston Chiu  1 ,  Zhikuan Zhang  8 ,  Norimichi Nomura  9 ,  Sandro Boland  2 ,  Umeharu Ohto  8 ,  Yannick Stahl  5 ,  Jurgen Wuyts  2 ,  Steven De Jonghe  10 ,  Annelies Stevaert  10 ,  Martijn J van Hemert  11 ,  Brenda W Bontes  11 ,  Patrick Wanningen  11 ,  G J Mirjam Groenewold  11 ,  Aneta Zegar  12 ,  Katarzyna Owczarek  12 ,  Sanjata Joshi  13 ,  Mohamed Koukni  2 ,  Philippe Arzel  2 ,  Hugo Klaassen  2 ,  Jean-Christophe Vanherck  2 ,  Ilse Vandecaetsbeek  2 ,  Niels Cremers  1 ,  Kim Donckers  1 ,  Thibault Francken  1 ,  Tina Van Buyten  1 ,  Jasper Rymenants  1 ,  Joost Schepers  1 ,  Krzysztof Pyrc  12 ,  Rolf Hilgenfeld  13 ,  Jean Dubuisson  3 ,  Berend-Jan Bosch  4 ,  Frank Van Kuppeveld  4 ,  Cecilia Eydoux  14 ,  Etienne Decroly  14 ,  Bruno Canard  14 ,  Lieve Naesens  10 ,  Birgit Weynand  15 ,  Eric J Snijder  11 ,  Sandrine Belouzard  3 ,  Toshiyuki Shimizu  8 ,  Ralf Bartenschlager  5  6  16 ,  Daniel L Hurdiss  4 ,  Arnaud Marchand  2 ,  Patrick Chaltin  2  17 ,  Johan Neyts  18
Affiliations
  • 1. Virology, Antiviral Drug & Vaccine Research Group, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.
  • 2. CISTIM Leuven vzw, Leuven, Belgium.
  • 3. CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Université de Lille, Lille, France.
  • 4. Virology Section, Infectious Diseases and Immunology Division, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
  • 5. Department of Infectious Diseases, Molecular Virology, Medical Faculty Heidelberg, University of Heidelberg, Heidelberg, Germany.
  • 6. German Center for Infection Research (DZIF), Heidelberg Partner Site, Heidelberg, Germany.
  • 7. Department of Microbiology, Immunology and Transplantation, VirusBank Platform, KU Leuven, Leuven, Belgium.
  • 8. Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan.
  • 9. Department of Cell Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • 10. Structural and Translational Virology Research Group, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.
  • 11. Molecular Virology Laboratory, Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.
  • 12. Virogenetics Laboratory of Virology, Malopolska Centre of Biotechnology, Jagiellonian University, Krakow, Poland.
  • 13. Institute of Molecular Medicine and German Center for Infection Research (DZIF), University of Lübeck, Lübeck, Germany.
  • 14. Architecture et Fonction des Macromolécules Biologiques (AFMB), Aix-Marseille Univ., CNRS, Faculté des Sciences Campus Luminy, Marseille, France.
  • 15. Department of Imaging and Pathology, Division of Translational Cell and Tissue Research, KU Leuven, Leuven, Belgium.
  • 16. German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • 17. Centre for Drug Design and Discovery (CD3), KU Leuven, Leuven, Belgium.
  • 18. Virology, Antiviral Drug & Vaccine Research Group, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium. [email protected].
  • # Contributed equally.
Abstract

The coronavirus membrane protein (M) is the main organizer of coronavirus assembly1-3. Here, we report on an M-targeting molecule, CIM-834, that blocks the assembly of SARS-CoV-2. CIM-834 was obtained through high-throughput phenotypic Antiviral screening followed by medicinal-chemistry efforts and target elucidation. CIM-834 inhibits the replication of SARS-CoV-2 (including a broad panel of variants) and SARS-CoV. In SCID mice and Syrian hamsters intranasally infected with SARS-CoV-2, oral treatment reduced lung viral titres to nearly undetectable levels, even (as shown in mice) when treatment was delayed until 24 h before the end point. Treatment of infected hamsters prevented transmission to untreated sentinels. Transmission electron microscopy studies show that virion assembly is completely absent in cells treated with CIM-834. Single-particle cryo-electron microscopy reveals that CIM-834 binds and stabilizes the M protein in its short form, thereby preventing the conformational switch to the long form, which is required for successful particle assembly. In conclusion, we have discovered a new druggable target in the replication cycle of coronaviruses and a small molecule that potently inhibits it.

Products